LPL Financial’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.38M | Sell |
163,493
-10,770
| -6% | -$348K | ﹤0.01% | 2571 |
|
|
2026
Q1 | $5.67M | Sell |
174,263
-5,593
| -3% | -$180K | ﹤0.01% | 2513 |
|
|
2025
Q4 | $6.33M | Sell |
179,856
-16,651
| -8% | -$590K | ﹤0.01% | 2336 |
|
|
2025
Q3 | $5.16M | Buy |
196,507
+58,136
| +42% | +$1.73M | ﹤0.01% | 2431 |
|
|
2025
Q2 | $3.67M | Buy |
138,371
+19,758
| +17% | +$520K | ﹤0.01% | 2561 |
|
|
2025
Q1 | $2.86M | Buy |
118,613
+21,911
| +23% | +$693K | ﹤0.01% | 2616 |
|
|
2024
Q4 | $3.89M | Buy |
96,702
+14,873
| +18% | +$848K | ﹤0.01% | 2272 |
|
|
2024
Q3 | $5.18M | Buy |
81,829
+24,326
| +42% | +$1.43M | ﹤0.01% | 1962 |
|
|
2024
Q2 | $3.05M | Buy |
57,503
+4,516
| +9% | +$296K | ﹤0.01% | 2242 |
|
|
2024
Q1 | $4.34M | Buy |
52,987
+3,352
| +7% | +$149K | ﹤0.01% | 1897 |
|
|
2023
Q4 | $924K | Buy |
49,635
+13,820
| +39% | +$181K | ﹤0.01% | 3111 |
|
|
2023
Q3 | $396K | Sell |
35,815
-2,557
| -7% | -$36.6K | ﹤0.01% | 3670 |
|
|
2023
Q2 | $622K | Buy |
38,372
+5,767
| +18% | +$121K | ﹤0.01% | 3244 |
|
|
2023
Q1 | $543K | Sell |
32,605
-11,045
| -25% | -$114K | ﹤0.01% | 3251 |
|
|
2022
Q4 | $410K | Buy |
43,650
+4,031
| +10% | +$18K | ﹤0.01% | 3430 |
|
|
2022
Q3 | $108K | Sell |
39,619
-74
| -0.2% | -$242 | ﹤0.01% | 4091 |
|
|
2022
Q2 | $115K | Buy |
39,693
+13,542
| +52% | +$33.5K | ﹤0.01% | 4102 |
|
|
2022
Q1 | $78K | Sell |
26,151
-1,365
| -5% | -$4.9K | ﹤0.01% | 4013 |
|
|
2021
Q4 | $127K | Sell |
27,516
-4,849
| -15% | -$27.2K | ﹤0.01% | 4087 |
|
|
2021
Q3 | $203K | Buy |
32,365
+5,470
| +20% | +$33.8K | ﹤0.01% | 3980 |
|
|
2021
Q2 | $161K | Buy |
26,895
+1,500
| +6% | +$8.91K | ﹤0.01% | 3961 |
|
|
2021
Q1 | $161K | Buy |
25,395
+11,000
| +76% | +$77.4K | ﹤0.01% | 3832 |
|
|
2020
Q4 | $81K | Hold |
14,395
| – | – | ﹤0.01% | 3704 |
|
|
2020
Q3 | $84K | Sell |
14,395
-4,000
| -22% | -$27.5K | ﹤0.01% | 3395 |
|
|
2020
Q2 | $133K | Sell |
18,395
-7,725
| -30% | -$51.3K | ﹤0.01% | 3243 |
|
|
2020
Q1 | $122K | Buy |
26,120
+8,450
| +48% | +$51.9K | ﹤0.01% | 2950 |
|
|
2019
Q4 | $142K | Sell |
17,670
-3,698
| -17% | -$27K | ﹤0.01% | 3178 |
|
|
2019
Q3 | $147K | Buy |
21,368
+4,183
| +24% | +$31.1K | ﹤0.01% | 3091 |
|
|
2019
Q2 | $143K | Sell |
17,185
-128,600
| -88% | -$1.1M | ﹤0.01% | 3110 |
|
|
2019
Q1 | $1.45M | Buy |
+145,785
| New | +$1.22M | ﹤0.01% | 1395 |
|
Other funds holding VKTX
LPL Financial's VKTX Position: Q2 2026 in Review
LPL Financial reduced its Viking Therapeutics (VKTX) stake by 6.2% in Q2 2026, selling an estimated $348K and leaving 163,493 shares worth $6.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2571.
LPL Financial first reported a position in VKTX in Q1 2019 and has held it in 30 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- LPL Financial held 163,493 shares of Viking Therapeutics worth $6.38M as of Q2 2026.
- LPL Financial sold 10,770 Viking Therapeutics shares in Q2 2026, an estimated $348K.
- Viking Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #2571 holding.
- LPL Financial first reported a position in Viking Therapeutics in Q1 2019 and has held it in 30 quarters since.
- 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.